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Abstract 
Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses 
considerable therapeutic challenges. Recent genetic and technological advances have 
provided insights into prostate cancer biology and have enabled the identification of novel 
drug targets and potent molecularly targeted therapeutics for this disease. In this article, we 
review recent advances in prostate cancer target identification for drug discovery and discuss 
their promise and associated challenges. We review the evolving therapeutic landscape of 
CRPC and discuss issues associated with precision medicine as well as challenges 
encountered with immunotherapy for this disease. Finally, we envision the future 
management of CRPC, highlighting the use of circulating biomarkers and modern clinical 
trial designs. 
Key points 
 Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and 
poses considerable therapeutic challenges. 
 Recent genetic and technological advances have provided insights into prostate cancer 
biology and enabled the identification of novel drug targets and potent molecularly 
targeted therapeutics for the disease. 
 Promising targets in CRPC include the androgen receptor and its variants, key 
signalling pathways such as phosphoinositide 3-kinase (PI3K)–AKT and WNT 
signalling, and DNA repair defects. 
 The therapeutic landscape of CRPC is evolving, with an increased focus on research 
into tumour heterogeneity, immuno-oncology, minimally invasive circulating tissue 
biomarkers, and modern clinical trial designs. 
 The use of state-of-the-art, high-throughput, genomic platforms enabling patient 
stratification will permit optimization of the development of current and future drugs 
for CRPC. 
Introduction 
Prostate cancer is the most common malignancy in men and a leading cause of cancer-related 
male mortality1. Although potentially curable when confined to the prostate, ~20% of patients 
will present with metastatic disease, and others develop disease progression despite local 
therapies such as surgery or radiotherapy2. 
In 1941, Charles Huggins first reported the beneficial effects of systemic androgen ablation in 
patients with advanced prostate cancer. This finding ultimately led to our understanding that 
blockade of the androgen receptor (AR) in prostate cancer represents an effective antitumour 
strategy. The current initial treatment of metastatic prostate cancer remains androgen-
deprivation therapy (ADT), either through surgical castration or through medical castration 
with anti-androgens or luteinizing hormone-releasing hormone (LHRH) agonists or 
antagonists. Although ADT leads to remissions lasting ~2–3 years, the disease inevitably 
progresses to castration-resistant prostate cancer (CRPC), which is associated with a poor 
prognosis and poses considerable therapeutic challenges. 
Recent advances in high-throughput, genome-wide profiling technologies, such as next-
generation sequencing and RNA interference screening, have provided considerable insights 
into prostate cancer biology and have enabled the identification of specific dependencies and 
vulnerabilities that can be exploited as novel drug targets3. Furthermore, technologies such as 
structure-based design have enabled the discovery and development of potent molecularly 
targeted therapeutics for these identified targets. It is envisioned that these advances will 
enable personalized treatments of patients with advanced prostate cancer — a possibility that 
is especially relevant because of the high intra- and inter-patient heterogeneity that exists in 
this disease4,5. 
In this Review, we summarize the different genomic techniques currently used to identify 
targets in CRPC. We focus on the most promising targets for prostate cancer drug discovery, 
including AR and its variants, on which many advanced and treatment-resistant tumours 
depend for growth and survival. We also highlight key signalling pathways as potential 
sources of targets, including phosphoinositide 3-kinase (PI3K)–AKT and WNT signalling, 
and DNA repair defects, as well as other emerging targets. We then discuss the evolving 
CRPC therapeutic landscape and explore issues associated with precision medicine. Finally, 
we envision the future care of patients with CRPC, which might involve the increased use of 
circulating biomarkers and modern clinical trial designs for improved outcomes. 
Genomic technologies 
In 2010, Taylor and co-workers reported a comprehensive approach to defining the genomic 
and transcriptomic profile of prostate cancer, which involved the analysis of more than 200 
tumours3. They mapped the prostate cancer oncogenome using arrays for measuring copy 
number and gene expression, as well as complete exon resequencing for identifying specific 
mutations3. This process identified distinct genomic alterations in the 138 evaluated genes. 
For example, the nuclear receptor co-activator NCOA2 was implicated as an oncogene in 
11% of tumours, and the transmembrane protease serine 2 (TMPRSS2)–ERG gene fusion was 
associated with a deletion at chromosome 3p14. This latter finding, when combined with 
expression data and focal deletion patterns, implicated forkhead box protein P1 (FOXP1), 
RING1 and YY1 binding protein (RYBP) and SHQ1 as potential cooperative tumour 
suppressors3. Subsequent analysis of copy number data revealed the functional relevance of 
these alterations in driving prostate cancer. Similar studies have used whole-genome 
sequencing (WGS)6,7 and, more recently, exome capture-based next-generation sequencing 
(NGS)8,9,10 to further map the prostate cancer genomic landscape. The characterization of 
CRPC by other methods, including RNA sequencing (RNA-seq)11 and metabolomics12, has 
also contributed to this body of knowledge. In this section, we provide an overview of the 
contribution provided by each of these respective technologies to drug discovery in CRPC.  
Whole-genome and whole-exome sequencing.  
Advances in NGS using massively parallel sequencing have increased throughput, enabling 
the detection of rare mosaic variants or mutations, at reduced cost. Thousands to millions of 
sequencing reactions can be performed in parallel, and cloning and template amplification of 
the sequenced DNA fragments can be fully automated or rendered unnecessary13. As a result, 
comprehensive tumour assessments with whole-exome sequencing (WES) and WGS are 
becoming increasingly widely available14. A recent WES study9 confirmed genomic 
aberrations in multiple commonly affected genes believed to be critically important in CRPC. 
These genes include those encoding the tumour suppressor p53 (TP53), AR, phosphatase and 
tensin homologue (PTEN), breast cancer type 2 susceptibility protein (BRCA2), serine-
protein kinase ataxia telangiectasia mutated (ATM), catenin-β1, retinoblastoma-associated 
protein (RB1), zinc finger homeobox protein 3 and APC. In addition, genes with as yet 
unclear roles in prostate cancer were identified. These genes include those encoding mixed 
lineage leukaemia protein 2 (MLL2), olfactory receptor 5L1 and cyclin-dependent kinase 12 
— although the lattermost may be a key DNA repair protein9. Loss of TP53 and/or RB1 
function has since been implicated in conferring resistance to the next-generation AR 
inhibitor enzalutamide (Xtandi; Astellas Pharma), possibly by priming prostate cancer cells to 
differentiate into more primitive, undifferentiated, small-cell cell types15. Conversely, 
aberrations of RB1 in CRPC cell lines are associated with sensitivity to mitotic inhibitors, 
indicating that taxanes and other tubulin-binding drugs have therapeutic potential in RB1-
variant tumours16. 
In a separate study6, complete sequencing of seven prostate cancer genomes and their paired 
non-cancer prostate tissue counterparts identified cancer-associated disruptions not 
previously implicated in prostate cancer. The analysis identified chromodomain-helicase-
DNA-binding protein 1 (CHD1), cell adhesion molecule 2, PTEN and membrane-associated 
guanylate kinase inverted 2 (MAGI2; a PTEN-interacting protein) as having a role in prostate 
cancer6. Recently, Stand Up To Cancer and the Prostate Cancer Foundation sponsored an 
international initiative for prostate cancer research, involving exome and transcriptome 
analyses of archived and fresh CRPC tumour biopsies17. This initiative provides a crucial step 
towards elucidating genomic variation patterns associated with prostate cancer and 
identifying novel actionable targets. 
Targeted DNA sequencing.  
Targeted DNA sequencing is a pragmatic, high-throughput and inexpensive method for 
identifying putative oncogenic aberrations of genes such as AR, BRCA2, ATM, CHK2 
checkpoint homologue (CHEK2), PI3K catalytic isoform p110α (PIK3CA), KRAS and 
BRAF3,18. Specific therapeutic strategies can then be developed on the basis of such data to 
target actionable genomic aberrations3. Recently, a novel NGS-based platform was applied to 
formalin-fixed paraffin- embedded tumour biopsy tissue to identify genomic alterations in 
known cancer-related genes19. The analysis identified AR alterations, the TMPRSS2–ERG 
fusion, PTEN loss, TP53 mutations, RB1 loss, MYC gain, PIK3CA mutation, BRCA2 loss and 
ATM mutations as particularly associated with prostate cancer aggressiveness19. This 
technology is particularly relevant clinically, as tissue biopsies are commonly processed 
using formalin-fixed paraffin-embedded methods20. 
Copy number alterations, including focal high-level amplification in genes such as AR and 
FOXA1, as well as deletion of PTEN and CHD1, have been identified in prostate cancer using 
comparative genomic hybridization array (aCGH)9,18,21. These recurrent, high-level gains or 
losses can indicate potential cancer drivers, such as AR amplification in prostate cancer22. In 
addition to AR, several clinical trials are evaluating whether loss of the tumour suppressor 
gene PTEN (as determined using fluorescent in situ hybridization (FISH) or 
immunohistochemistry) is a driver of CRPC by pharmacologically targeting downstream 
substrates along the PI3K–AKT signalling pathway23,24,25,26,27,28. However, early clinical data 
suggest that targeting the PI3K–AKT pathway at a single point may not be sufficient for 
antitumour activity owing to pathway feedback loops and signalling crosstalk; therapeutic 
strategies concurrently targeting AR and PI3K–AKT signalling may have superior antitumour 
activity29. In addition to aCGH, other genomic hybridization techniques, such as FISH, can 
isolate the position of genes to confirm their involvement in rearrangements, such as in the 
fusion genes TMPRSS2–ETV1 and TMPRSS2–ERG30. 
RNA-seq.  
RNA-seq uses NGS to characterize the RNA transcriptome, detecting expression of non-
coding RNA, gene fusions, somatic mutations and alternatively spliced forms11. Gene 
expression analyses can assess AR expression in CRPC and the continued dependence of 
CRPC cells on AR signalling31,32,33. RNA-seq has also demonstrated that increased 
expression of FOXA1, a cofactor known to interact directly with AR34, is associated with 
increased AR activity and cell growth in an androgen-depleted context. The resultant 
increased AR activity in this setting could cause resistance to castration, suggesting that 
FOXA1 could be a potential target for recurrent disease35. Furthermore, RNA-seq studies 
have identified many constitutively active splice variants of AR, which represent another 
mechanism of resistance of CRPC and thus another potential target in CRPC36,37. Notably, 
such targets would not have become evident through genomic analysis alone. The presence of 
these splice variants is associated with acquired resistance to the steroid 17α-hydroxylase 
(also known as CYP17A1) inhibitor abiraterone (Zytiga; Janssen Biotech) and the next-
generation AR inhibitor enzalutamide38,39. Moreover, worse prognosis and refractoriness to 
enzalutamide after abiraterone as well as to abiraterone after enzalutamide are associated with 
these splice variants38,39. By contrast, two studies (in small groups of patients) have indicated 
that these splice variants do not associate with taxane resistance40,41. Targeting the amino 
terminus of the AR splice variant products, potentially using peptidomimetics that inhibit AR 
interactions with other proteins, is now a major area of interest for CRPC drug discovery42. 
Long non-coding RNAs (lncRNAs) are not transcribed into proteins and can be expressed at 
very low levels, rendering them difficult to detect even by RNA-seq; however, lncRNAs 
seem to be important in prostate cancer43. For example, RNA-seq of prostate cancer 
xenografts identified a lncRNA called PCAT18 that appears to be prostate cancer-specific. 
Moreover, in vitro, LNCaP and C4-2 cells exhibited decreased cellular proliferation, 
migration and invasion upon PCAT18 silencing with small interfering RNA (siRNA), 
suggesting that this lncRNA could be a useful target for inhibiting metastatic prostate 
cancer43. Two other lncRNAs, PCANR1 and PCANR2, which regulate prostate cancer cell 
growth, were identified using integrative analysis of prostate cancer lncRNA expression 
profiles and clinical outcomes to predict potential drivers of progression44. Thus, PCANR1 
and PCANR2 are also promising therapeutic targets. High expression of the lncRNA 
SChLAP1 was also recently identified as a prognostic biomarker for metastatic disease 
progression of prostate cancer, supporting further investigation into its role as a potential 
biomarker for treatment intensification in aggressive prostate cancer45. 
Paired-end massively parallel transcriptome sequencing, which uses unique short sequences 
at the 5′ and 3′ ends of a DNA fragment, was used to search for potentially druggable driver 
gene fusions in ETS-rearrangement-negative prostate cancers. This approach identified two 
gene fusions involving RAF (SLC45A3–BRAF and ESRP1–RAF1) that may be responsive to 
RAF kinase inhibitors or MAPK/ERK kinase (MEK) inhibition46. RNA-seq has also revealed 
various alternative-splicing events, such as exon skipping in α-methylacyl-CoA racemase 
(AMACR), intron retention in KLK3 (the gene encoding prostate-specific antigen (PSA)) and 
alternative 5′ and 3′ splice sites47, which, together with their encoded proteins, may serve as 
potential novel therapeutic targets. 
 
 
Other RNA-based technologies.  
Short hairpin RNA (shRNA) and siRNA analyses and cancer outlier profile analyses 
(COPAs) have been used to unravel pathways involved in prostate cancer and to provide a 
basis on which to develop new drugs for CRPC. 
siRNA silencing of the expression of MLL, which acts as an epigenetic transcription factor, 
inhibits AR signalling in vitro9. siRNAs have also been used in mouse prostate epithelial cells 
to knock down the expression of the chromatin remodeller CHD1 to model a CHD1 deletion 
that is associated with wild-type speckle-type POZ protein (SPOP) in ETS gene family 
fusion-negative prostate cancers9,48,49. This Chd1 knockdown resulted in increased 
invasiveness and proliferation in the mouse prostate epithelial cells49. In addition, siRNAs 
targeting PCANR1 or PCANR2 inhibited growth in the androgen-dependent prostate cancer 
cell line LNCaP-abl44. siRNA knockdown of the epigenetic regulator enhancer of zeste 
homologue 2 (EZH2) in LNCaP-abl cells demonstrated a role of this factor as a co-activator 
of AR and other transcription factors50. This function of EZH2 is independent of its main role 
in silencing gene expression via its histone methyltransferase activity, and suggests a 
potential utility for combination therapy against EZH2 and AR50. 
An shRNA library approach characterized by Fellman and Lowe51 was used to identify 
specific shRNAs that synergize with decitabine, a DNA methyltransferase inhibitor, to 
promote cell death in human prostate cancer cells52. One such synergizing shRNA was 
specific for Aurora A kinase (AURKA), indicating a potential application of combining 
silencing gene expression and therapeutic agents, such as decitabine, in treating prostate 
cancer. Epigenetic regulators — including DNA methylation pathway mediators, histone-
modifying enzymes, chromatin-remodelling factors and structural chromosomal proteins — 
have a key role in cancer (reviewed in Ref. 53). The discovery of genomic aberrations in 
genes encoding these regulators has led to the evaluation of specific anticancer therapies such 
as bromodomain and extraterminal (BET) inhibitors. 
Bromodomains are protein domains that recognize monoacetylated lysine residues, such as 
those on the N-terminal tails of histones, and are required for protein–histone association and 
chromatin remodelling. The bromodomain-containing protein ATPase family AAA domain-
containing protein 2 (ANCCA; also known as ATAD2) has been identified as a potential 
therapeutic target owing to its androgen-mediated ability to stimulate expression of EZH2, 
which is a subunit of the polycomb repressive complex 2 (PRC2)54. PRC2 targets genomic 
regions for epigenetic silencing and has histone methyltransferase activity. Targeting the N-
terminal bromodomain of bromodomain-containing protein 4 (BRD4) with small-molecule 
BET inhibitors, such as JQ1 or I-BET762, in AR-signalling-competent CRPC cells led to 
antiproliferative effects and reduced cancer cell survival55,56. BRD4 interacts with the N-
terminal domain of AR; consequently, bromodomain inhibitors can disrupt AR recruitment to 
target genes, AR-mediated transcription and oncogenic AR-mediated induction of 
TMPRSS2–ERG transcription55. Furthermore, these inhibitors act downstream of AR, which 
may explain why BET inhibition has demonstrated greater efficacy in CRPC xenograft 
mouse models than the AR antagonist enzalutamide55. Phase I studies of BET inhibitors are 
currently ongoing57,58. 
Another RNA-based process to identify targets of interest is COPA. This technique can 
identify outlier gene expression profiles in prostate cancer based on the median and absolute 
deviation of gene expression profiles in benign prostate tissue30. COPA can identify 
translocations in which the promoter region from one gene is translocated to the intact coding 
region of an oncogene, thereby upregulating the expression of the latter. By applying COPA 
to the Oncomine database59 — a compendium of cancer microarray gene expression profiles 
— TMPRSS2–ETS rearrangements and high-level AR amplification were identifed30. Outlier 
meta-analysis (meta-COPA) of seven prostate cancer-profiling studies subsequently revealed 
transcriptional signatures that could distinguish between ETS-rearrangement-positive and 
ETS-rearrangement-negative tumours, and found the serine protease inhibitor Kazal-type 1 
(SPINK1) to be specifically upregulated in ETS-rearrangement-negative cancers60. SPINK1 
knockdown attenuated invasion in vitro and may therefore be a useful target in ETS-
rearrangement-negative prostate cancer60. 
Metabolomic technologies.  
In the same way that analyses of the cancer transcriptome has revealed targets not evident in 
the genome, it now seems likely that profiling of the cancer metabolome may also be 
informative12. One study used gene expression data from Oncomine Concept Maps61 to direct 
an analysis of biochemical pathways that are enriched in CRPC62. Mass spectrometry 
analysis and metabolic phenotyping identified 19 metabolites whose levels were altered in 
CRPC compared with androgen-dependent prostate cancer62. These metabolites mapped to a 
network of pathways that describe increased UDP glucuronosyltransferase (UGT) 
activity62,63. UGT activity in androgen-sensitive tissues is thought to be important for 
modulating the activity of androgens63. Although this pathway has previously been reported 
to be a potential predictor of treatment failure or disease recurrence62, it may also represent a 
potential source of targets for drug discovery in CRPC. 
Targets for drug discovery 
Rather than constituting a single disease, prostate cancer comprises multiple distinct and 
well-defined molecular subtypes that have different driver and passenger genomic alterations 
(Table 1). A recent study of the genomic landscape of metastatic CRPC has demonstrated 
that ~90% of prostate cancers harbour genomic aberrations that are potentially clinically 
actionable17. Using chemogenomic annotation and druggability assessment of key genetic 
aberrations, we find that CRPC is associated with a highly druggable network with multiple 
novel potential targets. A better understanding of these crucial molecular alterations will 
facilitate the translation of the most promising targets into disease molecular stratification and 
clinically relevant predictive biomarkers that will help ensure correct treatment allocation for 
a significant number of patients with CRPC. 
In this section, we focus on four main aspects of CRPC biology that we believe are the most 
promising and tractable from a drug discovery perspective: the AR, the PI3K–AKT pathway, 
WNT signalling and DNA repair defects (Fig. 1). Importantly, all are targets or pathways that 
may be modulated by existing drugs or investigational compounds (Table 2). 
The AR.  
AR is the most commonly altered gene in CRPC, with mutations occurring in nearly two-
thirds of cases17. Aberrations in AR that lead to the reactivation of AR signalling in CRPC 
include mutations, gene amplification or overexpression, and the expression of constitutively 
active AR splice variants64,65. The AR is a nuclear steroid hormone receptor that contains a 
central DNA-binding domain (DBD), a ligand-binding domain (LBD), a hinge region and a 
large N-terminal domain (NTD)66. AR-LBD mutants can be promiscuously activated by anti-
androgens (which activate, for example, AR-T878A and AR-W741C mutants)67,68, 
glucocorticoids (which activate AR-L702H)69, and adrenal androgens and progesterones 
(which activate AR-V715M)70. Mutations can also result in conformational changes to the 
AR; for example, the T878A mutation alters the stereochemistry of the LBD71. AR splice 
variants lacking the LBD72 can be constitutively active and result in the expression of AR-
target genes37,73. The AR splice variant 7 (arguably the most commonly expressed splice 
variant in prostate cancer) has been implicated in the development of CRPC and to resistance 
to ADT, enzalutamide and abiraterone74. 
Since the discovery that CRPC commonly remains AR-driven, there has been renewed 
interest in dissecting the specific underlying mechanisms of resistance75,76 and in developing 
novel AR-targeted therapies that can overcome such resistance77. Hormonal therapies 
currently available for CRPC treatment target either hormone production or prevent 
hormone-mediated activation of AR by blocking the LBD78. AR-LBD inhibition can be 
achieved through AR antagonists that now include the potent next-generation compounds 
enzalutamide and ARN-509. These compounds have high AR affinity and demonstrate in 
vitro and in vivo activity in bicalutamide-resistant models of prostate cancer with AR 
overexpression and mutant AR79,80. Inhibitors of androgen biosynthesis (and potentially also 
of AR), such as abiraterone and galeterone81, also decrease AR signalling. Recent evidence 
showed that abiraterone is converted in CRPC to the more active metabolite Δ4-abiraterone 
(D4A), which blocks multiple steroidogenic enzymes and directly inhibits the AR, providing 
an additional mechanism of action for the clinical activity of abiraterone82. 
The development of new inhibitors that act through non-LBD interfaces is an unmet clinical 
need. A recent study demonstrated that AR splice variant dimerization is key to AR splice 
variant signalling and involves a dimerization site near the DBD; targeting this interaction 
may therefore be of pharmacological utility in the future83. Targeting the AR NTD could 
provide an alternative way to block the receptor, with the advantage of bypassing resistance 
due to AR splice variant expression or AR mutations. However, this approach has been 
challenging because the NTD exhibits high flexibility and intrinsic disorder in solution, 
which together have prevented resolution of the NTD crystalline structure, and thus 
hampered virtual docking and other drug discovery strategies. 
One small-molecule inhibitor of the AR NTD, EPI-001, has undergone preclinical 
investigation83. The compound was identified from a library of marine sponge extracts that 
were screened for inhibitory activity against both ligand-dependent and ligand-independent 
activation of the AR by blocking the transactivation of the AR NTD by forskolin, interleukin-
6 (IL-6) or androgen83. EPI-001 was shown to covalently bind to the activation function 1 
(AF-1) region of the NTD to block interactions of proteins with the AR, and to reduce the 
transcriptional activity of both full-length and AR splice variants83. Importantly, EPI-001 
reduced androgen-induced proliferation and growth of CRPC xenografts expressing AR 
splice variants without significant toxic effects83,84. Concerns have been raised, however, that 
this compound has broad thiol-alkylating activity and has multiple mechanisms of action, 
including modulation of peroxisome proliferator-activated receptor-γ85. EPI-506, a derivative 
of EPI-001, has recently entered a phase I/II trial in patients with CRPC whose disease has 
progressed after prior enzalutamide or abiraterone therapy86. 
A surface exposed pocket on the AR DBD has also recently been proposed as an alternative 
site for AR inhibition. Small molecules designed to selectively bind to this pocket effectively 
block transcriptional activity of full-length and spliced AR forms87. As discussed above, 
inhibiting the bromodomain BRD4, which interacts with the AR NTD, is another potential 
strategy to target AR-meditated gene transcription in CRPC55. Another potential target in 
CRPC is the heat shock protein 70 (HSP70) co-chaperone B cell lymphoma 2 (BCL-2)-
associated athanogene 1 (BAG1), which stimulates AR activity (and regulates other steroid 
receptors)88. 
A novel strategy of interest has been the use of HSP90 inhibitors to target wild-type and 
mutant AR89,90. HSP90 is a chaperone protein that binds AR (as well as other proteins 
important in mediating prostate cancer progression), and maintains full-length AR in a high-
affinity ligand-binding conformation. Inhibition of HSP90 results in the degradation of full-
length AR and a suppression of AR signalling91,92. HSP90 inhibitors also result in depletion 
of AR splice variant 7 in in vitro and in vivo models93. A phase I study demonstrated 
preliminary antitumour responses in a range of advanced solid tumours, including CRPC, 
with the HSP90 inhibitor alvespimycin94. However, other phase I and phase II studies of 
HSP90 inhibitors have been generally disappointing, demonstrating poor patient tolerability 
and only modest antitumour activity95,96,97. Nonetheless, we envision that AR chaperone 
inhibitors that can potently and continuously suppress full-length AR and truncated AR splice 
variant 7 could have important antitumour activity in CRPC. 
Other strategies that do not target the AR NTD directly have also been explored in CRPC. 
For example, the calcium-dependent proteinase calpain has been shown to cleave the AR into 
an androgen-independent isoform98. Studies identified a calpain cleavage site in the hinge 
region of the AR, indicating that calpain-mediated proteolytic cleavage could represent a 
possible mechanism of post-transcriptional loss of the AR LBD, and that calpain inhibition 
could be potentially explored as a therapeutic strategy in CRPC98. Another strategy involves 
bypassing resistance due to AR splice variants by enhancing AR degradation with 
compounds such as ASC-J9 (also known as dimethylcurcumin), which targets AR splice 
variant 7 (Ref. 99). Blocking deubiquitylating enzymes, such as ubiquitin carboxy-terminal 
hydrolase 12, that are key to maintaining AR deubiquitylation and stability may also be a 
potential therapeutic target in CRPC100,101. 
As AR signalling pathways undergo modulation through complex protein–protein 
interactions, targeting intracellular networks downstream of AR activation could be a 
potential strategy for inhibiting aberrant AR activation and androgen-independent tumour 
growth102. One such potential target is the PTEN–AKT–FOXO1 axis. FOXO1 binds to the 
transcription activation unit 5 motif in the AR NTD in the nucleus and inhibits transcriptional 
activity of AR splice variants in prostate cancer cells in vitro103,104. In prostate cancer cells 
lacking PTEN, activated AKT phosphorylates FOXO1, resulting in its nuclear exclusion. 
This process facilitates the interaction of AR with co-activators, thereby favouring androgen-
independent activation of the AR. In the future, it is likely that improved genomic analysis 
will identify additional androgen-independent isoforms of AR, potentially revealing other 
potential drug targets in CRPC105. 
The PI3K–AKT signalling pathway.  
A well-established and druggable set of alterations in prostate cancer has been identified in 
the PI3K–AKT signalling pathway. PI3K pathway alterations in CRPC include PTEN loss, 
abnormalities in the genes encoding inositol polyphosphate 4-phosphatase type II and PH 
domain leucine-rich repeat-containing protein phosphatases, and PIK3CA aberrations3. Loss-
of-function mutations or deletions in PTEN are commonly observed in advanced prostate 
cancer (with loss of heterozygosity at the PTEN locus present in up to 60% of patients)9,18,106. 
NGS studies have also identified complex rearrangements that disrupt both PTEN and the 
gene encoding its interacting protein MAGI2 (Ref. 6). Pten loss in mouse models leads to 
precursor prostate cancer lesions, and these mice develop invasive carcinomas when such 
features are combined with other alterations such as aberrations in Erg, Tp53 and 
Myc107,108,109. 
Recent data also indicate that PTEN loss induces cellular senescence. However, infiltration of 
myeloid- derived suppressor cells can block this senescence. Specifically, Pten-null prostate 
tumours in mice are infiltrated by a population of CD11b+, glucocorticoid receptor 1-positive 
myeloid cells that protect a population of proliferating tumour cells from senescence, thus 
sustaining tumour growth. These myeloid-derived suppressor cells appear to infiltrate the 
prostate along a chemokine–chemokine receptor axis involving CXC chemokine receptor 
(CXCR2), and release IL-1 receptor antagonist, which inhibits senescence and drives 
proliferation110. These findings identify a novel network that is established by innate 
immunity and that controls senescence and tumour growth, suggesting that targeting innate 
immunity may provide a novel therapeutic opportunity for treating prostate cancers lacking 
PTEN. 
Critically, reciprocal feedback regulation between the PI3K–AKT pathway and AR signalling 
has been demonstrated in prostate cancers lacking PTEN, supporting the need for 
combinatorial antitumour strategies for such tumours28. In tumours lacking PTEN, PI3Kα 
activity is suppressed, and PI3K signalling is instead driven by PI3Kβ111. However, PI3Kβ 
inhibition only transiently inhibits AKT–mechanistic target of rapamycin (mTOR) signalling 
because it relieves feedback inhibition on upstream substrates and thus causes activation of 
PI3Kα and a rebound in downstream signalling. Therefore, combined PI3Kα and PI3Kβ 
inhibition may be required to effectively block the PI3K–AKT axis in PTEN-lacking 
tumours111. Several PI3K–AKT pathway inhibitors are currently under clinical investigation 
in CRPC, as single agents and/or in combination with the approved drugs enzalutamide and 
abiraterone (Table 2). 
WNT signalling.  
RNA-seq recently identified WNT–β-catenin signalling as a novel, functionally important 
pathway for androgen-independent prostate cancer progression9,112. Aberrations that result in 
WNT pathway activation, such as loss of function of the adenomatous polyposis coli protein 
(APC) and mutually exclusive mutations in the gene encoding β-catenin, have been identified 
in metastatic CRPC9,112. Moreover, uncommon WNT pathway-activating mutations, 
including RNF43 mutations and amplification or rearrangements of R-spondin family 
members (including RSPO2 and RSPO3) have been identified in metastatic CRPC9,112. 
Overall, there is potential for targeting WNT signalling in the subset of CRPCs with 
activation of this pathway. 
Multiple targeted strategies have been pursued to achieve this goal, including the inhibition of 
porcupine (PORCN), a membrane-bound O-acyltransferase enzyme required for WNT 
secretion, or of tankyrases (members of the poly(ADP-ribose) polymerase (PARP) family of 
proteins)113,114,115. Preliminary data from a phase I clinical trial of the first-in-class PORCN 
inhibitor WNT974 in patients with advanced solid tumours demonstrated a manageable 
safety profile, with side effects including dysgeusia, gastrointestinal symptoms, fatigue, 
asthenia and hypercalcaemia116. The phase I expansion cohort will restrict accrual to patients 
with cancers harbouring molecular aberrations that portend WNT ligand dependence, such as 
RNF43 mutations and RSPO fusions. 
DNA repair defects.  
Genomic aberrations of DNA defect repair genes have been reported in both CRPC and high-
risk localized disease. The most commonly aberrant genes are BRCA2 and ATM, and other 
genes involved in homologous recombination (HR) DNA repair, nucleotide excision repair 
(NER) and mismatch repair (MMR). Aberrations in genes involved in HR occur in up to 30% 
of CRPC cases17,19,117 and have important implications for antitumour treatment because HR 
defects in cancer cells may be exploited by anticancer therapeutics such as platinum therapy 
and PARP inhibitors through synthetic lethal approaches. Platinum drugs have been 
repeatedly reported to have a 20–30% response rate in advanced prostate cancer, but, until 
recently, no studies have pursued biomarkers predictive of the antitumour activity of such 
drugs. Other DNA repair defects, such as aberrations in genes involved in NER, may 
sensitize tumour cells to platinum therapy but not PARP inhibition118. 
Antitumour activity has been reported in a phase II clinical trial of the PARP inhibitor 
olaparib (Lynparza; AstraZeneca), with ~33% of evaluable patients with metastatic CRPC 
showing an antitumour response119. Importantly, most patients in this trial experiencing 
clinical benefit had tumours harbouring defects in HR DNA repair genes119. Data from other 
studies also suggest that PARP is required for ETS and AR function, suggesting that PARP 
inhibitors may have broader antitumour activity120,121. Multiple trials are now investigating 
PARP inhibition, either as a single agent or in combination with abiraterone, in men with 
CRPC who have sporadic or germline BRCA1 or BRCA2 mutations (Table 2). It is important 
to note that recent studies have surprisingly reported that 8–15% of metastatic prostate 
cancers have germline defects in actionable DNA repair genes; these findings will have an 
impact on the clinical care of men with advanced prostate cancer and will provide support for 
the routine germline testing of selected genes such as BRCA2 and ATM in this patient 
population17,122. 
In addition, abnormalities in genes involved in MMR and potentially other defects in DNA 
repair can also increase tumour mutational load, which can sensitize cancers to 
immunotherapy with multiple therapeutics targeting the programmed cell death 1 (PD1)–PD1 
ligand 1 (PDL1) axis or cytotoxic T lymphocyte-associated antigen 4 (CTLA4)123,124. So far, 
immune checkpoint- targeting treatments have shown limited evidence of antitumour activity 
in CRPC, with infrequent but impressive responses. Patient selection approaches in CRPC for 
immune-checkpoint targeting have yet to be pursued125. 
ETS gene rearrangements.  
The ETS family of transcription factors (including ERG, Friend leukaemia integration 1 
transcription factor (FLI1), ETV1 and ETV6) have important oncogenic roles in many 
prostate cancers126. Approximately 50% of prostate cancers harbour ETS rearrangements, 
most frequent of which are ERG rearrangements, and these are usually under the control of an 
androgen-regulated promoter element, most frequently TMPRSS2 (Ref. 30). ERG 
overexpression increases cell invasion, induces cell proliferation and AR expression127. 
Overexpression of ETS factors induces prostatic intraepithelial neoplasia in genetically 
engineered mouse models128 and, when combined with increased AR signalling or Pten loss, 
leads to the development of invasive prostate carcinomas in such mice108,129,130. Depletion of 
ETS factors in vitro reduces tumour cell motility and invasiveness, and decreases tumour 
growth in vivo. Inhibition of ETS oncogene signalling is a promising therapeutic strategy, 
with drug discovery efforts under way. 
Transcription factors have generally been considered undruggable targets; however, new 
strategies to modulate their transcriptional activity show promise131. These strategies include 
disrupting crucial protein–protein or DNA–protein interactions and restricting binding at the 
epigenetic level by modulating chromatin accessibility132. For example, dithiophene 
diamidine compounds can interfere with the ERG–DNA binding interaction132; DB1255, the 
most active of such compounds, interacts specifically with DNA at ERG-binding sites, 
inhibiting ERG–DNA complex formation132. Another strategy is the specific targeting of the 
TMPRSS2–ERG gene fusion junctions using liposomal nanovectors containing an optimized 
siRNA that causes sequence-specific silencing of gene expression of the two most common 
TMPRSS2–ERG fusion gene mRNA junctional isoforms (type III and type VI)133. 
Alternatively, targeting downstream effectors of TMPRSS2–ERG gene fusion or other 
proteins upregulated in ERG-positive cancers, such as the phospholipase 2 group VII 
(PLA2G7)134,135, has also been reported. PLA2G7 mRNA expression correlates with ERG 
expression in prostate cancer specimens, and PLA2G7 silencing by siRNA sensitized ERG-
rearrangement-positive and PLA2G7-positive VCaP cells to oxidative stress, reducing cell 
viability134,136. 
Drugs that exhibit antitumour activity in other malignancies by blocking additional specific 
pathways may also be evaluated for potential use in prostate cancers137. For example, the 
small molecule YK-4-279 inhibits the oncogenic FLI1 in Ewing sarcoma breakpoint region 1 
protein (EWS)–FLI1-rearranged Ewing sarcoma137. YK-4-279 blocks the binding of RNA 
helicase A to EWS–FLI1, induces apoptosis in Ewing sarcoma cells and reduces orthotopic 
xenograft growth. Similar to FLI1, ERG and ETV1 are also ETS transcription factors, and 
YK-4-279 has been shown to inhibit ERG- and ETV1-mediated transcription in ETV1-fusion-
positive LNCaP cells and in ERG-fusion-positive VCaP prostate cancer cells138. These results 
suggest that YK-4-279 could also have antitumour activity in prostate cancer138. 
The MAPK signalling pathway.  
Arguably less common in prostate cancer, but nevertheless still clinically relevant and 
potentially targetable, is oncogenic activation of RAS–RAF–MEK signalling. Such activation 
includes uncommon (1–2%) recurrent BRAF and RAF1 rearrangements as well as rare 
mutations of these genes and other aberrations of genes activating this pathway, including 
HRAS, sprouty-related, EVH1 domain-containing protein 1 (SPRED), SPROUTY, fibroblast 
growth factor (FGF) and FGF receptor (FGFR)46. As ETS proteins are downstream effectors 
of RAS–RAF–MEK–extracellular signal-regulated kinase (ERK) signalling, resistance to AR 
blockade in ETS-rearranged prostate cancer has been postulated to involve RAS–RAF–MEK 
signalling. Activation of the MAPK pathway could also activate ETS signalling in some ETS-
rearrangement-negative tumours. Evidence for this comes from a Kras-mutated, Pten-deleted 
genetically engineered mouse model that exhibited high ETV4 expression owing to co-
activation of PI3K and RAS signalling139. Studies of RAS–RAF–MEK inhibitors in CRPC 
are now needed to understand which subtypes of these cancers are driven by MEK, to further 
elucidate the importance of this pathway in CRPC. 
 
AURKA.  
AURKA inhibition is another possible strategy for targeting a specific type of prostate cancer 
known as neuroendocrine prostate cancer (NEPC). NEPC is an aggressive subtype of prostate 
cancer that can arise de novo or with castration resistance. NEPC frequently metastasizes to 
visceral organs, responds only transiently to chemotherapy and has a poor prognosis. ERG 
fusions have been reported in ~50% of NEPC cases140, suggesting that NEPC is clonally 
derived from adenocarcinoma and distinct from small-cell carcinomas. The cell cycle kinase 
AURKA and the transcription factor NMYC (encoded by MYCN) may cooperate to induce 
neuroendocrine differentiation in prostate cancer141. Co-amplification of AURKA and MYCN 
has been reported in NEPCs141,142; thus, AURKA inhibition may have antitumour activity 
against NEPC141 (Table 1). Meanwhile, AURKA inhibition has been shown to induce MYCN 
degradation in neuroblastoma models with antitumour activity143. 
The evolving therapeutic landscape 
The therapeutic landscape of CRPC is rapidly evolving. Several large phase III trials have 
now demonstrated survival benefit in patients with CRPC. For example, TAX327 144 tested 
the effects of the taxane chemotherapy docetaxel, and the COU-AA-301 145 and COU-AA-
302 146 trials evaluated the CYP17 inhibitor abiraterone in the post- and pre-docetaxel 
settings, respectively. The AFFIRM147 and PREVAIL148 trials investigated the next-
generation AR antagonist enzalutamide in the post- and pre-docetaxel settings, respectively, 
whereas the TROPIC149 trial assessed the effects of cabazitaxel post-docetaxel. The 
ALSYMPCA150 trial explored the alpha radiation-emitter radium-223-based 
radiopharmaceutical alpharadin (Xofigo; Bayer) in patients with bone-only metastases, and 
the IMPACT151 trial studied the effects of the autologous active cellular immunotherapy 
sipuleucel-T (Provenge; Dendreon) (Fig. 2). Most of these therapies were developed 
concurrently over a relatively short time period and have been approved by the US Food and 
Drug Administration (FDA). Furthermore, the recent CHAARTED trial showed that 
docetaxel combined with ADT, when initiated for hormone-sensitive disease, improves 
cancer control and confers improved overall survival compared with ADT alone152. These 
data are supported by the STAMPEDE trial, which demonstrated improved survival with 
docetaxel in this patient population153. 
There is an urgent need to define the optimal sequence of use of these agents to maximize 
patient benefit154. Such optimization should ideally be guided by scientific rationale through 
molecular subclassification of CRPC5 (Fig. 2). However, the absence of robust surrogate 
measures of survival and the lack of predictive biomarkers makes acquiring data for the 
sequential use of these agents challenging155. Other important factors that will influence the 
therapeutic landscape of CRPC include tumour heterogeneity and the potential application of 
novel approaches in immuno-oncology. 
Tumour heterogeneity.  
Treating prostate cancer is complicated by intra- and inter-patient tumour heterogeneity 
owing to the transcriptomic and proteomic diversity caused by the many varied genomic 
aberrations6,19. Although specific genetic aberrations are uncommon, different genomic 
lesions frequently converge on specific cellular functions and pathways156. Efforts are being 
made to identify the underlying mechanisms that drive each individual cancer and to develop 
analytically validated biomarkers that predict tumour response to treatments. NGS with high-
throughput characterization of the genome and transcriptome is a practical way of identifying 
specific targetable aberrations9, making precision medicine deliverable for patients with 
prostate cancer. 
Overall, it is now possible to subdivide CRPCs into those with AR aberrations, ETS gene 
rearrangements, PTEN loss and/or DNA repair defects (Fig. 2) and to match these subtypes 
with appropriate antitumour therapies. With the increased application of NGS and validation 
studies, the list of putative predictive biomarkers is rapidly growly. Molecular analyses of 
tumours from 'exceptional responders' can provide novel insights into underlying 
mechanisms of response to a particular drug, leading to the identification of predictive 
biomarkers157. 
Immuno-oncology.  
Intra-patient heterogeneity may be most prevalent in prostate cancers with DNA repair 
defects; some of these cancers have high mutational load, and studies of this patient 
subpopulation with immune checkpoint-targeting drugs is now indicated. There is a strong 
body of evidence supporting a role for immunotherapy in prostate cancer. Prostate cancer can 
be immunogenic, and histopathology samples have demonstrated infiltrating lymphocytes 
(including CD4+ cells, CD8+ cells and natural killer (NK) cells) and antigen-presenting cells 
(including dendritic cells and macrophages). The infiltrating CD4+ lymphocytes include 
regulatory T cells (Treg cells), which inhibit the immune response, suppressing and 
downregulating the induction and proliferation of antigen-specific effector T cells158. 
Clinically, prostate tumours with higher counts of Treg cells have a worse prognosis
159,160. By 
contrast, infiltrating NK cells play a major part in the antitumour response, and are associated 
with better prognosis161. Prostate cancer can evade the immune system by downregulating 
antigen presentation, escaping cytotoxic T cells, producing immunosuppressive cytokines 
(such as transforming growth factor-β) and recruiting Treg cells162. Activating the immune 
system against prostate cancer tumour-associated antigens, such as PSA, prostatic acid 
phosphatase (PAP), prostate-specific membrane antigen, prostate stem cell antigen and mucin 
1, may assist the immune system in overcoming these evasive processes. 
One example of an immunotherapy that is FDA-approved in CRPC is sipuleucel-T, a 
dendritic cell-based immunotherapy in which peripheral blood mononuclear cells are 
collected from the patient, enriched and incubated with PAP fusion protein PA2024 plus 
granulocyte–macrophage colony-stimulating factor (GM-CSF) for antigen-presenting cell 
activation and antigen processing, then infused back into the patient. Sipuleucel-T is well 
tolerated and improves overall survival by 4 months compared with placebo151. Benefit in 
overall survival is reported to correlate with numbers and activation of antigen-presenting 
cells after treatment, as well as with a post-baseline peripheral immune response to PA2024 
or PAP163. 
Novel approaches in immuno-oncology, such as immune-checkpoint inhibitors, have now 
transformed the therapeutic landscape in patients with advanced melanoma and in patients 
with non-small-cell lung cancer164,165,166. Such approaches have been explored in CRPC in 
nonselected patients. Ipilimumab (Yervoy; Bristol-Myers Squibb) is a human 
immunoglobulin G1 monoclonal antibody that binds to and blocks CTLA4. CTLA4, a key 
negative regulator of T cell responses, is constitutively expressed on Treg cells and mediates 
their immunosuppressive effect167. Early-phase studies in CRPC with ipilimumab showed a 
number of patients with a >50% decline in levels of serum PSA and one complete response 
according to the RECIST (Response Evaluation Criteria in Solid Tumors) guidelines. 
However, in a phase III trial against placebo, there was no significant effect of ipilimumab in 
the overall survival primary end point, although the drug did show signs of antitumour 
activity168,169,170. 
Multiple other immunotherapies are currently being evaluated in CRPC, including the PD1 
inhibitor pembrolizumab (Keytruda; Merck & Co.), which has recently demonstrated activity 
in other cancers including MMR-defective cancers124,171,172. Optimal patient selection, 
treatment timing and sequence of immunotherapies remain under investigation, as does their 
application in combination immunotherapy strategies, in which they may act synergistically 
in CRPC. 
PROSTVAC-VF immunotherapy comprises two recombinant viral vectors encoding 
transgenes encoding PSA and three immune co-stimulatory molecules: B7.1 (also known as 
CD80), intercellular adhesion molecule 1 (ICAM1) and lymphocyte function-associated 
molecule 3 (LFA3). PROSTVAC-VF is initially delivered in a vaccinia-based vector, 
followed by six immune boosts in a fowlpox-based vector, with each dose given in 
conjunction with granulocyte–macrophage colony- stimulating factor (GM-CSF). A phase II 
study comparing PROSTVAC-VF to control empty vectors showed an 8.5-month 
improvement in median overall survival in men with minimally symptomatic CRPC173; a 
phase III study is currently under way174. 
Outlook 
These are exciting times in the management of CRPC, with a collection of antitumour agents 
now available for use. There are several lessons to be learnt from other cancers that are 
beginning to be managed successfully in a bona fide personalized medicine framework175. 
There now needs to be clear prioritization of tumour drivers for therapeutic targeting with 
consideration of the complex cancer clonal and subclonal structures involved, including the 
study of evolving subclonal dynamics during treatment176. Molecular stratification of patient 
groups will clearly be key to successful drug development. Moreover, strategies to identify 
potential escape mechanisms will be important to direct the optimal sequential application of 
drugs. This approach may involve the molecular characterization of sequential tumour 
biopsies or circulating plasma DNA or circulating tumour cells (CTCs) in therapeutic clinical 
trials175 to deliver precision medicine for patients with CRPC (Fig. 2). 
Minimally invasive and tissue biomarkers in CRPC.  
Although tumour biopsies remain the gold standard for CRPC tissue sampling, issues 
concerning accessibility and the ease of safe rebiopsy remain challenging and rate-limiting. 
In marrow-infiltrating CRPC, bone biopsies have been assessed for AR and CYP17 
expression using immunohistochemistry177. In addition, assessments of AR copy number 
using polymerase chain reaction, TMPRSS2–ERG status using FISH, and testosterone levels 
using mass spectrometry, as well as exome and transcriptome studies, have been 
performed177. Extensive research has also now been undertaken with several non-invasive 
strategies, including the use of CTCs178,179, plasma DNA180,181,182, urine183 and 
exosomes184,185 for predictive biomarker analyses. 
Although most studies of CTCs in CRPC have focused on CTC enumeration in the past, the 
spotlight has now switched towards the molecular characterization of CTCs, using techniques 
such as multicolour FISH and NGS186. CTCs also have the potential to serve as intermediate 
end point biomarkers, and may accurately reflect clinical benefit. This finding can facilitate 
earlier 'go–no-go' drug development decisions to be made on treatment efficacy, thus 
potentially reducing costs and accelerating drug approval. Other potential applications for 
CTC assessments include the study of treatment effects ex vivo through the generation of 
primary cell cultures from CTCs or through CTC-derived xenografts. In one study, prostate 
cancer biopsy specimens and CTCs were cultured in a 3D organoid system that retained the 
histological and molecular features of the patient specimen187. WES of the specimen was then 
carried out to identify genetic variability and aberrations187. The first seven fully 
characterized organoid lines were shown to recapitulate the molecular diversity of prostate 
cancer subtypes, including TMPRSS2–ERG fusion, SPOP mutation, SPINK1 overexpression 
and CHD1 loss. Such an approach may potentially enable the development of a wide range of 
patient-derived prostate cancer lines amenable to genetic and pharmacological testing187. 
In the future, it is likely that whole-genomic, transcriptomic and proteomic single-cell 
analyses will become more feasible and cost-effective, enabling the serial monitoring of 
molecular changes of individual CTCs to antitumour treatments in real time. Genomic 
profiling of individual CTCs, cell-free DNA and tissue biopsies may be used to investigate 
tumour heterogeneity and to monitor clonal evolution during treatment (for example, to track 
the development of resistant clones associated with disease progression)175,188,189. Indeed, it is 
now possible to perform whole-genome analysis of cell-free DNA190. Such studies can reveal 
gene copy-number aberrations, AR amplification and AR mutations that are associated with 
resistant disease190. Recent studies have also developed and validated prognostically useful 
gene expression signatures of CRPC that are linked to inflammatory and immune responses; 
it has been postulated that mRNA expression profiles may also be acquired from CTCs and 
tumour-released exosomes191,192,193. Such signatures could be used as predictive or 
pharmacodynamic biomarkers for immunotherapy treatments. 
Modern clinical trial designs.  
Future trials must take into account the histopathological and genotypic characteristics of 
CRPC and assess the impact of intra- and inter-patient heterogeneity on therapeutic 
outcomes. Potential strategies may include adaptive and umbrella trials that assess putative 
predictive biomarkers to deliver precision medicine. These trials can be challenging to 
perform and involve navigating through complex regulatory hurdles, gaining access to 
multiple drugs from different sources and off-label use of novel agents or approved drugs — 
all potential pitfalls194. 
Ultimately, despite advances in our understanding of prostate cancer and of potential 
therapeutic targets, there continues to be a high attrition rate in drug development for CRPC. 
For example, a phase III trial of cabozantinib (Cabometyx/Cometriq; Exelixis) was 
terminated early owing to inefficacy, despite demonstrating single-agent antitumour 
activity195. Clinical trials with novel and rationally based designs may reduce drug 
development failures by selecting patients predicted to respond. An example of such an 
approach is the phase II TOPARP study, which was based on the concept of synthetic 
lethality, whereby exploitable DNA repair defects exist in CRPC, as with other tumour types 
such as ovarian and breast cancers196,197. In this trial, the PARP inhibitor olaparib was 
initially used in nonselected patients with metastatic CRPC before a preplanned analysis 
identified a biomarker-defined sensitive subgroup, followed by a prospective validation 
cohort. Such novel trial designs will become increasingly important, particularly as our 
understanding of the inter-patient heterogeneity of CRPC reveals its underlying complexity. 
Future clinical trials must also evaluate intratumour heterogeneity and clonal evolution within 
a patient, collecting multiple tumour biopsies, cell-free DNA, exosomes, CTCs and urinary 
tumour DNA. Another strategic approach involves rapid autopsy programmes when patients 
succumb despite drug treatment. Together, these strategies provide opportunities to obtain 
tumour tissue that would otherwise not be amenable to biopsy, to allow a retrospective 
construction of the genomic landscape and interactions with the microenvironment. 
Conclusions 
We have entered a time of rapid change and progress in prostate cancer medicine. 
Importantly, modern technological advances have also provided us with major new insights 
into CRPC biology. Several effective new drugs have been approved over the past few years 
and there are now multiple novel investigational agents undergoing evaluation, as well as 
new targets being exploited in drug discovery that could provide further benefit to patients 
with CRPC. Tackling issues of drug resistance to different antitumour agents, as well as the 
exploration of immuno- oncology strategies in CRPC, will continue to be critical challenges. 
In addition, rational combinations — either concomitantly or sequentially — to overcome 
resistance will be important, alongside the longitudinal genomic profiling of circulating 
plasma DNA to support adaptive drug administration. Importantly, because patients with 
CRPC are now regularly living more than 5–10 years with this disease, we need to continue 
to focus not only on how long patients live but also on how well they are living, to maximize 
quality of life. We envision that the use of state-of-the-art, high-throughput, genomic 
platforms that enable patient stratification will facilitate the optimal use of current and future 
drugs. This may be further enhanced through rational antitumour treatment strategies, with 
novel clinical trial designs that implement the 'pharmacological audit trail', which provides a 
rational framework for assessing the risk of failure of the development of a new agent, 
driving further improvements in patient care175,198. 
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Figure 1: The cellular biology of prostate cancer. 
The complex underlying cellular biology and signalling cascades associated with castration-resistant 
prostate cancer (CRPC) are illustrated. Several of the molecules depicted — for example, poly(ADP-
ribose) polymerase (PARP), the androgen receptor (AR) and molecules in the phosphoinositide 3-
kinase (PI3K)–AKT pathway — have been implicated as possible drug targets in CRPC. 4EBP1, 
eukaryotic translation initiation factor 4E-binding protein 1; APC, adenomatous polyposis coli 
protein; ARE, androgen response element; AR-SV, AR splice variant; BAD, BCL-2-associated 
agonist of cell death; BCL-2, B cell lymphoma 2; BCL-X, BCL-2-like protein 1; BET, bromodomain 
and extraterminal; BRD, bromodomain-containing protein; CXCL, CXC chemokine ligand; CXCR, 
CXC chemokine receptor; DNMT, DNA methyltransferase; DSH, dishevelled; eIF4E, eukaryotic 
translation initiation factor 4E; EZH2, enhancer of zeste homologue 2; FKHR, forkhead; GR, 
glucocorticoid receptor; GRE, glucocorticoid response element; GSK3β, glycogen synthase kinase 3β; 
HDAC, histone deacetylase; HIF1α, hypoxia-inducible factor 1α; HSP, heat shock protein; IGF1, 
insulin-like growth factor 1; IGF1R, IGF1 receptor; IRS1, insulin receptor substrate 1; JMJD2, 
Jumonji domain-containing protein 2A; LRP, lipoprotein receptor-related protein; LSD1, lysine-
specific histone demethylase 1A; MAPK, mitogen-activated protein kinase; MDM2, double minute 2 
protein; MEK, MAPK/ERK kinase; mTORC, mechanistic target of rapamycin complex; NF-κB, 
nuclear factor-κB; p70S6K, p70 ribosomal S6 kinase; PDK1, 3-phosphoinositide-dependent protein 
kinase 1; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-trisphosphate; 
PTEN, phosphatase and tensin homologue; RHEB, Ras homologue enriched in brain; RTK, receptor 
tyrosine kinases; S6RP, S6 ribosomal protein; SUZ12, suppressor of zeste 12; TMPRSS2, 
transmembrane protease serine 2; TSC, tuberous sclerosis. 
 
 
  
Figure 2: CRPC treatment in the present and in the future. 
Until 2010, the gold standard treatment for castration- resistant prostate cancer (CRPC) was docetaxel 
chemotherapy. However, the recent US approval of abiraterone, enzalutamide, cabazitaxel, alpharadin 
(also known as radium-223) and sipuleucel-T now provides a range of agents for patients with CRPC 
(part a). In the future (part b), this landscape will inevitably change substantially, as various factors, 
including patient factors, resistance to prior therapies and local drug availability, determine the 
sequence of delivery of drugs. In addition, efforts will be made to molecularly stratify patients to 
matched targeted therapies. For example, tumours can be characterized using tumour-targeted next-
generation sequencing or other exome, transcriptome or whole-genome analyses to identify DNA 
repair defects and to determine mutational load. Determination of truncal clonal and subclonal 
aberrations, androgen receptor (AR) signalling status and AR splice variant expression (for example, 
using immunohistochemical analysis or RNA in situ hybridization), and evaluation of the tumour 
stroma and infiltrated immune cells such as CD8+ cells and myeloid derived suppressor cells 
(MDSCs) should also inform treatment strategies. The decision for treatment transition should 
incorporate standard clinicopathological measures, novel biomarkers (such as circulating tumour cells 
(CTCs) and circulating plasma DNA) and patient-derived xenografts and organoid cultures. CSF1R, 
macrophage colony-stimulating factor 1 receptor; CXCR, CXC chemokine receptor; mTORC, 
mechanistic target of rapamycin complex; PARP, poly(ADP-ribose) polymerase; PI3K, 
phosphoinositide 3-kinase; TAZ, transcriptional co-activator with PDZ-binding motif; YAP1, Yes-
associated protein 1. 
 
